Navigation Links
PDC Biotech GmbH Announces Close of Series A Financing
Date:10/31/2009

VIENNA, AUSTRIA, October 30, 2009 / b3c newswire / - PDC Biotech GmbH (PDC) today announced the close of a Series A financing of over 4 million. MIG Verwaltungs AG (Munich) and Edmond de Rothschild Investment Partners (Paris) co-led the round.

Proceeds from the financing will be used to complete preclinical work and the first clinical study of the companys lead compound, PDC31 which is being developed for the treatment of preterm labour and primary dysmenorrhea. The company is expecting to conclude the remaining preclinical work early in mid 2010 and then conduct the Phase I/II trial.

PDC31 is a peptide antagonist of the prostaglandin F2a (FP) receptor, the lead in a series of FP antagonists exclusively licensed to PDC Biotech GmbH from Theratechnologies, (TSX: TH), a Canadian biopharmaceutical company.

Ms. Patricia Griffin and Ms Diane Kalina, co-founders of PDC stated: We are delighted to have such outstanding investors who understand the potential of our company and who are able to provide the necessary capital to advance our programs despite the difficult financing market.

The company was previously awarded 1 million in seed funding from the Austria Wirtschaftsservice (AWS) and a grant of 517,000 from the Zentrum fr Innovation und Technologie (ZIT; an agency of the City of Vienna for promotion of innovation and technology). The total funds raised since inception amount to over 5.56 million (approx. CDN $8.9 million).

Preterm Labour
Preterm labour is defined as regular uterine contractions associated with cervical changes occurring before 37 weeks of gestation. Preterm birth, which is associated with increased risk of neonatal morbidity and mortality, is most often preceded by preterm labour.

Primary Dysmenorrhea
Primary dysmenorrhea is a disabling condition found in women of childbearing age with a high prevalence among adolescent females. Severe abdominal pain is caused by frequent and prolonged uterine contractions that decrease blood flow to the myometrium resulting in ischemia.


About PDC Biotech GmbH - www.pdcbiotech.com
PDC Biotech GmbH is a privately held Austrian biopharmaceutical development company focussed in women's health. The company moved to Austria in May 2008 following the securing of 1 million in seed funding from the Austria Wirtschaftsservice (the federal promotional bank of the Republic of Austria). The company was founded by two Canadian industry entrepreneurs, Diane Kalina and Patricia Griffin. PDC is developing a novel compound which targets the prostaglandin F2a receptor for the treatment of preterm labour and primary dysmenorrhea.


About Edmond de Rothschild Investment Partners - www.edrip.fr
Paris-based Edmond de Rothschild Investment Partners (EdRIP) is dedicated to minority investments into privately-owned companies. It has currently more than 750 million under management which is being invested primarily as life sciences venture capital and growth capital. Its Life Science Team of seven professionals has over 90 years of cumulated experience in the life science industry and has a proven track record in biotechnology and medical technology investments. The team has approximately 270 million under management, recently raised its 155 million BioDiscovery 3 fund, which is to be invested during the next years. Edmond de Rothschild Investment Partners is part of the group La Compagnie Financire Edmond de Rothschild.

About MIG Verwaltungs AG - www.mig.ag
MIG AG is a Munich-based venture capital firm with an investment focus on early to mid-stage life science and technology companies in German-speaking Europe. As one of Germany's most active venture capital firms, MIG AG has invested in over twenty innovative companies in Austria and Germany. Based in Munich, the company initiates and manages venture capital funds with a volume exceeding 300 million.


For more information, please contact
PDC Biotech GmbH
Diane Kalina +43 (1)8900077-20
dkalina@pdcbiotech.com


'/>"/>
b3c newswire

Related biology news :

1. Media source impacts ag biotech communication
2. KINAXO Biotechnologies and Bayer Vital GmbH Collaborate in Phosphoproteomics Biomarker Identification
3. GATC Biotech AG is investing more than 5 million euros in its Constance site to double the companys floor space
4. Anti-biotech groups obstruct forest biotechnology
5. GenWay Biotech obtains exclusive rights to AMDLs DR-70 cancer test in US and Canada
6. Genome sequencing of fungus with biotechnological applications
7. Biotech scientists team with curators to stem decay of worlds art, cultural heritage
8. Genetic Engineering & Biotechnology News reports on the trend toward predictive toxicogenomics
9. Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics
10. CU-Boulder, biotech firm team up on python project in search for human cardiac therapeutics
11. Genetic Engineering & Biotechnology News reports on novel hit-to-lead drug discovery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... medical technologies, services and solutions to the healthcare market. The company's primary focus ... distribution, manufacturing, sales and marketing strategies that are necessary to help companies efficiently ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
Breaking Biology Technology: